Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof

1. A method for treating a B-cell proliferative disease in a subject, comprising administering to the subject in need thereof Compound 1,

wherein the B-cell proliferative disease is selected from a group consisting of chronic lymphocytic leukemia, small lymphocytic lymphoma, mantle cell lymphoma, Waldenström's macroglobulinemia, marginal zone lymphoma, and follicular lymphoma; and

Compound 1 is administrated at a dose of 160 mg twice a day (BID).

2. The method of claim 1 , wherein Compound 1 has a purity of at least 99.3%.

3. The method of claim 1 , wherein Compound 1 has a purity of at least 99.5%.

4. The method of claim 3 , wherein the B-cell proliferative disease is mantle cell lymphoma.

5. The method of claim 4 , wherein the subject has received at least one prior therapy.

6. The method of claim 3 , wherein the B-cell proliferative disease is Waldenström's macroglobulinemia.

7. The method of claim 3 , wherein the B-cell proliferative disease is marginal zone lymphoma.

8. The method of claim 7 , wherein the subject has received at least one prior therapy.

9. The method of claim 8 , wherein the marginal zone lymphoma is relapsed or refractory marginal zone lymphoma.

10. The method of claim 3 , wherein the B-cell proliferative disease is chronic lymphocytic leukemia.

11. The method of claim 3 , wherein the B-cell proliferative disease is small lymphocytic lymphoma.

12. The method of claim 3 , wherein the B-cell proliferative disease is follicular lymphoma.

13. The method of claim 3 , wherein an amorphous form or a crystalline form of Compound 1 is administered.

14. The method of claim 13 , wherein a crystalline form of Compound 1 is administered.

15. The method of claim 14 , wherein the crystalline form exhibits an X-ray powder diffraction pattern comprising diffraction peaks having 2θ angle values at 14.8±0.2°, 16.4±0.2° and 21.4±0.2°.

16. The method of claim 15 , wherein the crystalline form exhibits an X-ray powder diffraction pattern comprising diffraction peaks having 2θ angle values at 14.8±0.2°, 15.6±0.2°, 16.4±0.2° and 21.4±0.2°.

17. The method of claim 16 , wherein the B-cell proliferative disease is mantle cell lymphoma, wherein the subject has received at least one prior therapy.

18. The method of claim 16 , wherein the B-cell proliferative disease is Waldenström's macroglobulinemia.

19. The method of claim 16 , wherein the B-cell proliferative disease is relapsed or refractory marginal zone lymphoma, wherein the subject has received at least one prior therapy.

20. The method of claim 16 , wherein the B-cell proliferative disease is chronic lymphocytic leukemia, or small lymphocytic lymphoma.

21. The method of claim 13 , wherein an amorphous form of Compound 1 is administered.

22. The method of claim 21 , wherein the amorphous form of Compound 1 has a mid-point temperature of a glass transition temperature at 79.7° C.

23. The method of claim 22 , wherein the amorphous form has an enantiomeric excess value of at least 97%.

24. The method of claim 23 , wherein the B-cell proliferative disease is mantle cell lymphoma, wherein the subject has received at least one prior therapy.

25. The method of claim 23 , wherein the B-cell proliferative disease is Waldenström's macroglobulinemia.

26. The method of claim 23 , wherein the B-cell proliferative disease is relapsed or refractory marginal zone lymphoma, wherein the subject has received at least one prior therapy.

27. The method of claim 23 , wherein the B-cell proliferative disease is chronic lymphocytic leukemia, or small lymphocytic lymphoma.

28. The method of claim 3 , wherein Compound 1 is administered orally.